{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T14:10:13Z","timestamp":1772201413457,"version":"3.50.1"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Analysis of adverse events (AEs) in randomized controlled trials (RCTs) related to psoriasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>A cross-sectional meta-epidemiological study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources<\/jats:title>\n                    <jats:p>We conducted a comprehensive search of PubMed and the Cochrane Database for studies meeting our eligibility criteria from January 2020 to July 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Eligibility criteria<\/jats:title>\n                    <jats:p>RCTs specifically investigating non-articular psoriasis were included. All long-term extension (LTE) studies were excluded; however, psoriasis-related RCTs utilizing both double-blind and open-label designs were incorporated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main outcome measures<\/jats:title>\n                    <jats:p>We assessed (1) general characteristics of psoriasis RCTs; (2) the Adverse Event Reporting Completeness Index (AERCI) Score for reporting completeness; (3) specific details of AEs; (4) factors associated with reporting completeness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 187 psoriasis RCTs published between 2020 and 2025 were included. The median AERCI-Core score was 6.00 (IQR: 2.00\u20138.00), indicating suboptimal overall reporting quality, with only 26.2% of studies rated as high quality. Adherence to individual reporting items varied widely, with particularly low rates observed for AE management measures (16.0%), timing of AE onset (20.3%), outcome\/resolution (26.7%), and use of standardized coding systems (31.6%). Multivariable linear regression identified journal impact factor [\u03b2 = 0.27, 95% CI (0.13, 0.40),\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001] and pustular psoriasis subtype [\u03b2 = 1.85, 95% CI (0.10, 3.60), P = 0.038] as independent predictors of higher reporting completeness.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study identified inadequate reporting of adverse events in RCTs for non-articular psoriasis. After adjusting for confounding variables, a higher journal impact factor and a focus on pustular psoriasis were positively associated with the complete reporting of AEs. To enhance the utility of safety data for clinical decision-making, future trials should rigorously implement the Consolidated Standards of Reporting Trials\u2014Harms 2022 (CONSORT-Harms 2022) recommendations, thereby providing patients with more balanced information on the benefits and harms of psoriasis therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1734221","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T13:13:37Z","timestamp":1772198017000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Reporting of the harms from randomized controlled trials for psoriasis: a cross-sectional meta-epidemiological study"],"prefix":"10.3389","volume":"13","author":[{"given":"Zhaoxin","family":"Yang","sequence":"first","affiliation":[{"name":"Hospital of Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yalan","family":"Xiong","sequence":"additional","affiliation":[{"name":"Hospital of Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Shen","sequence":"additional","affiliation":[{"name":"Hospital of Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zilin","family":"Cheng","sequence":"additional","affiliation":[{"name":"Hospital of Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yangyingqi","family":"Dai","sequence":"additional","affiliation":[{"name":"Hospital of Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pingsheng","family":"Hao","sequence":"additional","affiliation":[{"name":"Hospital of Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhipeng","family":"Hu","sequence":"additional","affiliation":[{"name":"Hospital of Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1111\/1346-8138.15840","article-title":"Psoriasis: Comorbidities","volume":"48","author":"Yamazaki","year":"2021","journal-title":"J Dermatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3390\/ijms19010058","article-title":"Cardiometabolic comorbidities in psoriasis and psoriatic arthritis","volume":"19","author":"Puig","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"Jama"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.3390\/ijms21051690","article-title":"Efficacy and safety of biologics for psoriasis and psoriatic arthritis and their impact on comorbidities: a literature review","volume":"21","author":"Kamata","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2020.03.013","article-title":"Randomized controlled trials","author":"Zabor","year":"2020","journal-title":"Chest"},{"key":"B7","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1136\/bmj.316.7126.201","article-title":"Understanding controlled trials. Why Are Randomised Controlled Trials Important?","volume":"316","author":"Sibbald","year":"1998","journal-title":"Bmj"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e024537","DOI":"10.1136\/bmjopen-2018-024537","article-title":"Analysis and reporting of adverse events in randomised controlled trials: a review","volume":"9","author":"Phillips","year":"2019","journal-title":"BMJ Open"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1001\/archinternmed.2009.306","article-title":"Reporting of safety results in published reports of randomized controlled trials","volume":"169","author":"Pitrou","year":"2009","journal-title":"Arch Intern Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"111861","DOI":"10.1016\/j.jclinepi.2025.111861","article-title":"Where Are the Harms? Underreporting of adverse events in clinical trials investigating targeted therapy for endocrine and metabolic disorders: an observational study","volume":"185","author":"Pavi\u0107","year":"2025","journal-title":"J Clin Epidemiol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/bmjebm-2024-113497","article-title":"Patient-reported outcomes and acupuncture-related adverse events are overlooked in acupuncture randomised controlled trials: a cross-sectional meta-epidemiological study","author":"Duan","year":"2025","journal-title":"BMJ Evid Based Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"3957","DOI":"10.1200\/JCO.2013.49.3981","article-title":"Adherence to consort adverse event reporting guidelines in randomized clinical trials evaluating systemic cancer therapy: a systematic review","volume":"31","author":"P\u00e9ron","year":"2013","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1007\/s40264-018-0680-0","article-title":"Inadequate harms reporting in randomized control trials of antibiotics for pediatric acute otitis media: a systematic review","volume":"41","author":"Hum","year":"2018","journal-title":"Drug Saf"},{"key":"B14","doi-asserted-by":"publisher","first-page":"111406","DOI":"10.1016\/j.jclinepi.2024.111406","article-title":"Quality of reporting and concordance between sources of adverse events in the treatment of moderate-to-severe psoriasis: a cross-sectional study of rcts from a cochrane systematic review","volume":"173","author":"Beytout","year":"2024","journal-title":"J Clin Epidemiol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e073725","DOI":"10.1136\/bmj-2022-073725","article-title":"Consort harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomised trials","volume":"381","author":"Junqueira","year":"2023","journal-title":"Bmj"},{"key":"B16","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jclinepi.2010.03.005","article-title":"The quality of safety reporting in trials is still suboptimal: survey of major general medical journals","volume":"64","author":"Haidich","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.eplepsyres.2011.06.015","article-title":"Reporting of adverse events in randomised controlled trials of antiepileptic drugs using the consort criteria for reporting harms","volume":"97","author":"Shukralla","year":"2011","journal-title":"Epilepsy Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1093\/jac\/dkp191","article-title":"Reporting of adverse events in randomized controlled trials of highly active antiretroviral therapy: systematic review","volume":"64","author":"Chowers","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1016\/j.pain.2012.08.009","article-title":"Adherence to consort harms-reporting recommendations in publications of recent analgesic clinical trials: an acttion systematic review","volume":"153","author":"Smith","year":"2012","journal-title":"Pain"},{"key":"B20","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1001\/jama.285.4.437","article-title":"Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas","volume":"285","author":"Ioannidis","year":"2001","journal-title":"Jama"},{"key":"B21","doi-asserted-by":"publisher","first-page":"20","DOI":"10.7326\/0003-4819-143-1-200507050-00006","article-title":"Reporting of harm in randomized, controlled trials of nonpharmacologic treatment for rheumatic disease","volume":"143","author":"Ethgen","year":"2005","journal-title":"Ann Intern Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1186\/s12891-015-0825-6","article-title":"The effect of journal impact factor, reporting conflicts, and reporting funding sources, on standardized effect sizes in back pain trials: a systematic review and meta-regression","volume":"16","author":"Froud","year":"2015","journal-title":"BMC Musculoskelet Disord"},{"key":"B23","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1080\/09593985.2016.1222472","article-title":"Funding is related to the quality, conduct, and reporting of trial reports in musculoskeletal physical therapy: a survey of 210 published trials","volume":"32","author":"Maas","year":"2016","journal-title":"Physiother Theory Pract"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e0299806","DOI":"10.1371\/journal.pone.0299806","article-title":"Endorsements of five reporting guidelines for biomedical research by journals of prominent publishers","volume":"19","author":"Wang","year":"2024","journal-title":"PLoS ONE"},{"key":"B25","doi-asserted-by":"publisher","first-page":"858","DOI":"10.3109\/02713683.2014.957777","article-title":"Positive results bias and impact factor in ophthalmology","volume":"40","author":"Mimouni","year":"2015","journal-title":"Curr Eye Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1213\/ANE.0b013e3182468fc6","article-title":"Jr","volume":"114","author":"De Oliveira","year":"2012","journal-title":"Anesth Analg"},{"key":"B27","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/bjd.20971","article-title":"Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial","volume":"186","author":"Augustin","year":"2022","journal-title":"Br J Dermatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1159\/000502130","article-title":"Dipeptidyl peptidase-4 inhibition in psoriasis patients with diabetes: a double-blind randomized controlled trial","author":"Lynch","year":"2021","journal-title":"Dermatology"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20863","article-title":"Efficacy and safety of me3183, an oral phosphodiesterase 4 inhibitor, in patients with plaque psoriasis","author":"Papp","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jaad.2022.01.005","article-title":"A multicenter, randomized, double-blinded, placebo-controlled, dose-ranging study evaluating the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis","volume":"87","author":"Zhang","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1186\/s13063-021-05343-0","article-title":"Improving analysis practice of continuous adverse event outcomes in randomised controlled trials - a distributional approach","volume":"22","author":"Chis Ster","year":"2021","journal-title":"Trials"},{"key":"B32","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.jaad.2019.03.009","article-title":"Navigating the landscape of core outcome set development in dermatology","volume":"81","author":"Prinsen","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s40257-024-00876-x","article-title":"Efficacy and safety of brodalumab, an anti-interleukin-17 receptor a monoclonal antibody, for palmoplantar pustulosis: 16-week results of a randomized clinical trial","volume":"25","author":"Okubo","year":"2024","journal-title":"Am J Clin Dermatol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1093\/bjd\/ljae402","article-title":"Efficacy and safety of the ustekinumab biosimilar abp 654 in patients with moderate-to-severe plaque psoriasis: a randomized double-blinded active-controlled comparative clinical study over 52 weeks","volume":"192","author":"Blauvelt","year":"2025","journal-title":"Br J Dermatol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1111\/exd.14828","article-title":"Secukinumab vs. guselkumab in the complete resolution of ustekinumab-resistant psoriatic plaques: the arrow study","volume":"32","author":"Krueger","year":"2023","journal-title":"Exp Dermatol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1177\/1740774509344101","article-title":"Recommendations for safety planning, data collection, evaluation and reporting during drug, biologic and vaccine development: a report of the safety planning, evaluation, and reporting team","volume":"6","author":"Crowe","year":"2009","journal-title":"Clin Trials"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e068983","DOI":"10.1136\/bmj-2021-068983","article-title":"Visualising harms in publications of randomised controlled trials: consensus and recommendations","volume":"377","author":"Phillips","year":"2022","journal-title":"Bmj"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1111\/1346-8138.16566","article-title":"Efficacy and safety of apremilast and phototherapy versus phototherapy only in psoriasis vulgaris","volume":"49","author":"Morita","year":"2022","journal-title":"J Dermatol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1080\/09546634.2020.1826392","article-title":"Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type 2 diabetes: a randomized-controlled trial","volume":"33","author":"Lin","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2680","DOI":"10.1080\/09546634.2022.2043546","article-title":"Serum drug levels and anti-drug antibodies in the context of dose tapering by interval prolongation of adalimumab, etanercept and ustekinumab in psoriasis patients: results of the condor trial","volume":"33","author":"Atalay","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"B41","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.jclinepi.2021.12.023","article-title":"Improving the analysis of adverse event data in randomized controlled trials","volume":"144","author":"Cornelius","year":"2022","journal-title":"J Clin Epidemiol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s40264-018-00792-0","article-title":"A comparison study of algorithms to detect drug-adverse event associations: frequentist, bayesian, and machine-learning approaches","volume":"42","author":"Pham","year":"2019","journal-title":"Drug Saf"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1734221\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T13:13:38Z","timestamp":1772198018000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1734221\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":42,"alternative-id":["10.3389\/fmed.2026.1734221"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1734221","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"article-number":"1734221"}}